Open Access Open Access  Restricted Access Subscription or Fee Access

Acinetobacter baumannii: A Multidrug-Resistant invasive pathogen

Deepak Chaudhary

Abstract


Acinetobacter baumannii, a multidrug-resistant and invasive bacteria, is one of the leading causes of nosocomial infections in today's healthcare system. Multiple virulence factors, including as porins, capsules, and cell wall lipopolysaccharide, enzymes, biofilm development, motility, and iron-acquisition mechanisms, all contribute to pathogenesis in A. baumannii infections. These virulence factors aid the organism's resistance to adverse environmental circumstances and allow for the development of severe illnesses. Parallel to the rising incidence of A. baumannii infections, complex and diversified resistance mechanisms in this pathogen are well established, with key antibiotic classes being less effective. Pharmacogenomic and computational biology are appealing approaches for identifying common pharmacological targets and peptide-vaccine possibilities in pathogens. Vaccine design is shifting away from whole pathogen or whole antigen vaccines and toward peptide or epitope-based vaccinations that are specific, safe, and simple to make. A comparative genomics technique was utilised to find conserved protein signatures across five genomes.


Keywords


Acinetobacter baumannii, Pharmacogenomic, protein, computational, computational, multidrug-resistant (MDR).

Full Text:

PDF

References


Erridge C, Moncayo-Nieto O, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. JMedMicrobiol 2007; 56:165–71.

Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007; 28:293–8.

Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteraemia. Infect Control Hosp Epidemiol 2007; 28:7139.

Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007; 26:793–800.

Blot S, Vandewoude K, Colardyn F. Nosocomial bacteraemia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29:471–5.

Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97–103.

Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case–control study. J Hosp Infect 2009; 73:143–50.

Albrecht MA, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006; 203:546–50. 224 N.C. Gordon, D.W. Wareham / International Journal of Antimicrobial Agents 35 (2010) 219–226

Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59:52530.

Wareham DW, Bean DC, Khanna P, Hennesy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27:607–12.

Loh LC, Yii CT, Lai KK, Seevaunnamtum SP, Pushparasah G, Tong JM. Acinetobacter baumannii respiratory isolates in ventilated patients are associated with prolonged hospital stay. Clin Microbiol Infect 2006; 12:5978.

Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care 2006;10: R48.

Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrugresistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55:1619–29. Morgan DJ, Weisenberg SA, Augenbraun MH, Calfee DP, Currie BP, Furuya EY, et al. Multidrug-resistant Acinetobacter baumannii in New York City—10 years into the epidemic. Infect Control Hosp Epidemiol 2009; 30:196–7.

Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008;14(Suppl. 6):2–8.


Refbacks

  • There are currently no refbacks.